Last week, Chinese genomics company Singleron Biotechnologies, which develops single-cell multi-omics platform technologies and helps translate them to the clinic, announced it had acquired Proteona Pte. Ltd. Based in Singapore, Proteona is also focused on the single-cell side of things, offering single-cell biomarker discovery services to clinical and translation researchers around the world.
What Singleron Gets: Access to Proteona’s network, which currently extends throughout the US, Canada, Europe, and Asia, strengthening its position beyond China, as well as access to the company’s expert insights on the biopharma market and its single-cell multi-omic analysis tech.
Statements from representatives of both companies show they looking forward to what the union will bring, particularly relating to single-cell based precision medicine.
“We are very excited about the opportunity to work with Proteona since both companies are focused on bringing breakthrough single cell technologies to the clinic,” said Dr. Nan Fang, CEO and co-founder of Singleron, in a March 7 statement announcing the acquisition. “Proteona’s expertise in generating clinically-relevant insights together with pharma partners and clinicians has enormous synergy with Singleron’s vision to advance precision medicine by combining single-cell multi-omics technologies and data science.”
Single-cell analysis is important to clinical research as it provides more information on how each cell contributes to different biological functions, crucial for better understanding how disease develops and, in turn, allowing for the creation of more effective treatments for those diseases.
According to other media sources, financial details and other terms of the deal were not released.